Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.

about

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.

Item

http://www.wikidata.org/entity/Q36383018

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Ocular toxicities associated w ...... a with management suggestions.

@ast

Ocular toxicities associated w ...... a with management suggestions.

@en

type

Item

label

Ocular toxicities associated w ...... a with management suggestions.

@ast

Ocular toxicities associated w ...... a with management suggestions.

@en

prefLabel

Ocular toxicities associated w ...... a with management suggestions.

@ast

Ocular toxicities associated w ...... a with management suggestions.

@en

P1476

Ocular toxicities associated w ...... ta with management suggestions

@en

P2093

Andrew Whyte

http://www.w3.org/2001/XMLSchema#string

Chen Fu

http://www.w3.org/2001/XMLSchema#string

David S Hong

http://www.w3.org/2001/XMLSchema#string

Goldy C George

http://www.w3.org/2001/XMLSchema#string

Jared Lee

http://www.w3.org/2001/XMLSchema#string

Kenneth Hess

http://www.w3.org/2001/XMLSchema#string

P2860

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Erlotinib in previously treated non-small-cell lung cancer

P304

58709-58727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17634

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

D S Gombos

P577

2017-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28549348

http://www.w3.org/2001/XMLSchema#string

28938590

http://www.w3.org/2001/XMLSchema#string

P932

5601686

http://www.w3.org/2001/XMLSchema#string